Pliant Therapeutics, Inc. (PLRX)
NASDAQ: PLRX · Real-Time Price · USD
1.355
-0.115 (-7.82%)
Mar 31, 2025, 1:13 PM EDT - Market open

Company Description

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States.

The company’s lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of αvß6 and αvß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.

It also develops PLN-1474, an oral, small-molecule selective inhibitor of αvß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins αvß8 and αvß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies.

Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Pliant Therapeutics, Inc.
Pliant Therapeutics logo
Country United States
Founded 2015
IPO Date Jun 3, 2020
Industry Biotechnology
Sector Healthcare
Employees 171
CEO Bernard Coulie

Contact Details

Address:
260 Littlefield Avenue
South San Francisco, California 94080
United States
Phone 650 481 6770
Website pliantrx.com

Stock Details

Ticker Symbol PLRX
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001746473
CUSIP Number 729139105
ISIN Number US7291391057
Employer ID 47-4272481
SIC Code 2834

Key Executives

Name Position
Dr. Bernard Coulie M.B.A., M.D., Ph.D. President, Chief Executive Officer and Director
Dr. Keith Lamont Cummings M.B.A., M.D. Chief Financial Officer
Johannes P. Hull Chief Business Officer
Dr. Eric A. Lefebvre M.D. Chief Medical Officer
Dr. Rik Derynck Ph.D. Scientific Founder and Member of Scientific Advisory Board
Dean Sheppard M.D. Scientific Founder and Member of Scientific Advisory Board
Bill DeGrado Ph.D. Scientific Founder and Member of Scientific Advisory Board
Hal Chapman M.D. Scientific Founder and Member of Scientific Advisory Board
Delphine Imbert Ph.D. Chief Technical Officer
Christopher S. Keenan Vice President of Investor Relations and Corporate Communications

Latest SEC Filings

Date Type Title
Mar 13, 2025 8-K Current Report
Mar 13, 2025 8-A12B Registration of securities
Mar 10, 2025 SCHEDULE 13D Filing
Mar 7, 2025 SCHEDULE 13G/A Filing
Mar 3, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 3, 2025 10-K Annual Report
Mar 3, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 13, 2025 8-K Current Report
Feb 10, 2025 8-K Current Report